Optimizing clinical and economic outcomes in the management of primary immunodeficiency diseases: Taking a closer look at the role of immunoglobulin replacement therapy

Patients with primary immunodeficiency diseases (PIDDs) require expensive, lifelong administration of immunoglobulin replacement. Choosing an administration route that works for the patients will result in adherence with therapy. Choosing an appropriate dose can result in an infection-free patient who is less costly than one whose infections are not controlled.